Evaluation of Influenza A H1N1 infection and antiviral utilization in a tertiary care hospital
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
BELUCCI, Talita Rantin
MARRA, Alexandre R.
EDMOND, Michael B.
YOKOTA, Paula Kiyomi Onaga
MAFRA, Ana Carolina Cintra Nunes
SANTOS, Oscar Fernando Pavao dos
Citação
BMC INFECTIOUS DISEASES, v.18, article ID 579, 6p, 2018
Resumo
Background: Influenza A H1N1 infections carry a significant mortality risk. This study describes inpatients with suspected and confirmed Influenza A H1N1 infection who were prescribed oseltamivir, the risk factors associated with infection, the association between infection and mortality, and the factors associated with in-hospital mortality in infected patients. Methods: This study was a matched case-control study of hospitalized patients who underwent real-time polymerase chain reaction testing for Influenza A H1N1 and were treated with oseltamivir from 2009 to 2015 in a tertiary care hospital. Cases (patients with positive Influenza A H1N1 testing) were matched 1:1 to controls (patients with negative test results). Results: A total of 1405 inpatients who underwent PCR testing and received treatment with oseltamivir were identified in our study and 157 patients confirmed Influenza A H1N1. Almost one third of patients with Influenza A H1N1 were diagnosed in the pandemic period. There was no difference in mortality between cases and controls. Immunocompromised status, requirement of vasoactive drugs, mechanical ventilation, acute hemodialysis, albumin administration, surgical procedures and thoracic procedures and length of stay were associated with increased risk of death in Influenza A H1N1 infected patients. Conclusions: We found no increased risk of mortality for patients with proven Influenza A H1N1 when compared to similar patients without confirmed Influenza.
Palavras-chave
Influenza a H1N1, Oseltamivir, Hospitalized patients
Referências
- Alvarez-Lerma F, 2017, J HOSP INFECT, V95, P200, DOI 10.1016/j.jhin.2016.12.017
- Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
- Coleman BL, 2017, ANTIVIR RES, V140, P158, DOI 10.1016/j.antiviral.2017.01.025
- Garnacho-Montero J, 2018, J CRIT CARE, V48, P172, DOI 10.1016/j.jcrc.2018.08.017
- Halekoh U, 2006, J STAT SOFTW, V15, P1
- McGeer AJ, 2009, CLIN INFECT DIS, V48, pS14, DOI 10.1086/591852
- Ministerio da Saude. Secretaria de Vigilancia em Saude, 2013, INFL MON AT SEM EP
- Ministerio da Saude. Secretaria de Vigilancia em Saude, 2015, INFL MON AT SEM EP
- Ministerio da Saude. Secretaria de Vigilancia em Saude, 2014, INFL MON AT SEM EP
- Pires EM, 2014, HOSP ISRAELITA A EIN
- Rewar S, 2015, ANN GLOB HEALTH, V81, P645, DOI 10.1016/j.aogh.2015.08.014
- Rodriguez-Rieiro C, 2012, HUM VACC IMMUNOTHER, V8, P443, DOI 10.4161/hv.18911
- Sekhon JS, 2011, J STAT SOFTW, V42, P1
- Shah NS, 2015, INFECT CONT HOSP EP, V36, P1251, DOI 10.1017/ice.2015.170
- Zazueta-Garcia R, 2014, J INFECT DEV COUNTR, V8, P331, DOI 10.3855/jidc.3726